Advertisement

Picture EBD Group BIO-Europe Spring 2020 Paris BEU2020 650x75
Document › Details

Wilex AG. (7/15/10). "Press Release: Wilex AG Receives Tender Offer for a Mandatory Takeover Bid by dievini Hopp BioTech holding". Munich.

Region Region Germany
Organisations Organisation Wilex AG
  Today Heidelberg Pharma AG (FSE: WL6)
  Group Heidelberg Pharma (Group)
  Organisation 2 Dievini Hopp BioTech Holding GmbH & Co. KG
  Group HOPP Group (family of Dietmar Hopp)
Products Product cancer drug
  Product 2 cancer test
     


WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) received a tender offer for a mandatory takeover bid by dievini Hopp BioTech Holding GmbH & Co. KG, Walldorf, Germany (dievini) late yesterday evening. The German Federal Financial Supervisory Authority (BaFin) has reviewed and approved the offer document.

dievini is obliged under section 35 para. 2 German Securities Acquisition and Takeover Act (WpÜG) to make an offer to acquire all of WILEX's bearer shares after exceeding the control threshold of 30% of the Company's voting rights on 2 June 2010. dievini now has an equity interest of 35.65% in WILEX.

The offer price is EUR 4.10 per share and exceeds the statutory minimum price of EUR 4.07. The acceptance period for the offer starts to run on 15 July 2010 and ends at midnight CET on 12 August 2010. The Executive Management Board and the Supervisory Board of WILEX AG will issue a statement regarding the mandatory offer.

The offer document will be posted solely in German on the web pages of both the prospective buyer (www.dievini.com) and WILEX AG (www.wilex.de) from 15 July 2010 onwards and made available for inspection, at no charge, by DZ BANK AG Deutsche Zentral-Genossenschaftsbank, Frankfurt/Main, Abteilung F/GTKS, Platz der Republik, 60265 Frankfurt/Main, Germany, Fax: + 49 (0) 69 7447 3685 ("DZ BANK").


About WILEX AG

WILEX AG is a biopharmaceutical company based in Munich and is listed at the Frankfurt Stock Exchange at the Regulated Market / Prime Standard. WILEX's mission is to develop drugs with a low side effect profile and targeted treatment of different types of cancer as well as diagnostic agents for specific detection of tumours. The Company's product candidates are based on antibodies and small molecules. WILEX has an attractive product pipeline which includes both drug and diagnostic candidates: A pivotal Phase III study with REDECTANE® has been completed and positive data published. RENCAREX® is undergoing a Phase III registration trial. Positive MESUPRON® Phase II data in the indication pancreatic cancer have been published and another Phase II trial in breast cancer is ongoing. The MEK inhibitor WX-554 has completed a Phase I trial. A further oncology project (PI3K inhibitor WX-037) is in preclinical development and three antibody programmes are in research. WILEX aims within a few years to be able to finance its research and development programmes from its operating cash flow. Website: http://www.WILEX.com, ISIN DE0006614720 / WKN 661472 / Symbol WL6

Contact

WILEX AG
Corporate Communications
Katja Arnold (CIRO)
Grillparzerstr. 10
81675 Munich
Germany
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-Mail: investors@wilex.com


This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

   
Record changed: 2017-04-02

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

More documents for Heidelberg Pharma (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px




» top